Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Patisiran-LNP Pregnancy Surveillance Program

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Inclusion Criteria:

• Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy

Exclusion Criteria:

• There are no exclusion criteria for participation in this program.